

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 May 2002 (02.05.2002)

PCT

(10) International Publication Number
WO 02/34221 A1

- (51) International Patent Classification⁷: A61K 7/16, (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US00/29384
- (22) International Filing Date: 25 October 2000 (25.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicant (*for all designated States except US*): THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): LAWLOR, Thomas, Mark [IE/GB]; 456 London Road, Ashford, Middlesex TW15 3AD (GB).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (74) Agents: REED, T, David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/34221 A1

(54) Title: DENTAL CARE COMPOSITIONS

(57) Abstract: The present invention relates to non volatile compositions that comprises: i) from about 0.5 % to about 60 % by weight, of a silicone resin; ii) from about 0.1 % to about 30 %, by weight, of a silicon gum; iii) from about 0.1 % to about 95 %, by weight, of a non volatile polysiloxane fluid which has a viscosity from about 1cStk to about 1000cStk; and from about 0.01 % to about 50 %, by weight, of an oral care active selected from teeth colour modifying substances, anti-tartar agents, anti-plaque agents, fluoride ion sources, anti-microbial agents, nutrients, antioxidants, H-2 antagonists, analgesics, anti-viral agents, mucosally absorbed pharmacological agents and mixtures thereof. A second aspect of the present invention relates to the user of non volatile oral care silicone compositions in the oral cavity to treat the hard and soft tissue surfaces wherein the composition comprises: (i) from about 0.5 % to about 60 %, by weight, of a silicone resin; (ii) from about 0.1 % to about 30 %, by weight of a silicone gum; (iii) from about 1cStk to about 1000cStk. Compositions of the present invention are useful for providing a substantive composition on the surfaces of the oral cavity which can provide prophylactic, therapeutic or cosmetic benefits.

WO 02/34221

PCT/US00/29384

1

Dental Care Compositions

Field of the Invention

The present invention relates to oral care compositions which comprise a silicone resin, a silicone gum and a silicone fluid, and to the use of such oral care compositions to treat the hard and soft tissue surfaces of the oral cavity. More particularly, this invention relates to silicone oral care compositions which form a substantive film on the surface of the teeth or gums treating these surfaces and which are readily removed by brushing, rinsing or eating at the end of the treatment period. According to one aspect of this invention the compositions can also comprise an oral care active and as such can provide sustained delivery of this active to the tissues of the oral cavity. Compositions of the present invention are particularly useful for delivering of oral care actives which either enhance the appearance of the teeth or provide therapeutic and / or prophylactic benefits.

Background

Many consumers have a good understanding of the prophylactic, therapeutic and cosmetic benefits of maintaining high standards in oral hygiene. These benefits include reduction in caries, plaque, gingivitis and tartar; treating hypersensitivity; freshening breath; whitening teeth and removing stains; remineralising teeth and the like. To date, a wide variety of oral care products are available which, over the short term, aid the maintenance of good oral hygiene by delivering various oral care substances or actives to the soft and hard tissues of the oral cavity. In general such products exist in the form that they are used by the consumer themselves either at-home or away from the home and/or are administered by dentists / hygienists as part of their professional routine of oral hygiene treatments. Specific examples of such products, particularly those for use by the consumer themselves, include dentifrices containing for example anti-caries actives and/or anti-bacterial plaque reducing actives; mouth washes containing breath freshening

WO 02/34221

PCT/US00/29384

2

actives and/or anti-bacterial actives; and chewing gums containing tooth whitening actives.

The most frequently used oral hygiene treatments are those administered by the consumer themselves and it is usual that these are practised, in the Western world, either once or twice a day. However, many of the processes which lead to a deterioration in the tissues of the oral cavity are on-going and, as such, can only be effectively treated, either prophylactically or therapeutically, by continuous attention which is impractical or by the use of long lasting treatments. To date, conventional product forms do not typically provide long lasting, prolonged or sustained therapeutic, prophylactic and /or cosmetic treatment benefits. Instead the preparations take effect only for the relatively short period of time during which the teeth are being cleaned or the mouth is being rinsed and, after product use, the active level on the hard and soft oral tissues diminishes rapidly. Thus, until now, the only way to achieve sustained active release with conventional products has been to periodically reapply the product or to use a special delivery device or containment means such as a mouthpiece. It would therefore be desirable to have an oral care product comprising one or more active substances which is itself substantive within the oral cavity and wherein the oral care product has a pleasant mouth feel such that its aesthetics are acceptable for long term use in the oral cavity. It is also desirable to have a substantive oral care product wherein the active substances are released over a sustained period of time and thus able to provide a long lasting benefit. Finally it would be desirable if this oral care product was easily removed at the end of the treatment period such that no damage is sustained to the hard or soft tissues of the oral cavity in removing the product and such that the oral care product is suitable for home use by the consumer without the need for professional assistance. Furthermore such compositions would be especially useful in the many less well developed areas of the world where prophylactic professional dental hygiene is less commonly available.

Several attempts have previously been made to enhance the substantivity of active components of oral care products within the oral cavity. These attempts include the use

WO 02/34221

PCT/US00/29384

3

of water soluble film forming polymers to deliver various actives for example bleaching agent (US 5,425,953, PCT/CN97/00); bactericidal pharmacological agent (US 5,438,076); anti-plaque cationic bactericide (EP 0,864,315); fluoride ions (US 5,989,535) etc. However, because the above systems are water soluble they readily dissolve in saliva and therefore their degree of durability is relatively low and they can not provide long term delivery of the active ingredient. In addition, their water soluble nature precludes them from being used in conjunction with oral care actives that would be unstable in water based films, for example sodium percarbonate. A second strategy that has been disclosed in the art for the improvement of the substantivity of actives within the oral cavity is the use of materials which are able to adsorb to the tissue. For example US 3,956,480 discloses compositions in which cationic germicide and anionic polymer are adsorbed onto the hydroxyapatite surface of the teeth; EP0736544 discloses the use of antibodies to adhere to specific proteins in the oral cavity for example in the pellicle structures; EP 1,027,877 and US 5,139,768 disclose compositions comprising hydrophobic polymers for example cellulosic or carbonyloxycarbonyl polymers to achieve substantivity; and WO 93/24103 discloses an antimicrobial agent supported on an inert oxide synthetic particulate which adsorbs onto the tooth enamel. However, these methods are limited in that the materials tend to have a preferred affinity for the hard tissues of the oral cavity and furthermore they can be limited in the type of oral care actives that can be incorporated. Higher degrees of durability have been achieved by the use of hard protective coatings on the teeth. For example US 5,401,528 discloses the polymerisation of organically modified silicic acid polycondensates to coat the teeth; similarly US 5,888,491 discloses the use of polymers grafted to polysiloxane chains for providing a highly substantive coating to the hard tissues within the oral cavity. However these complete coating systems are often unsuitable for home use, feel unnatural and the coating itself can still be subject to the deleterious effect of plaque-causing bacteria.

Silicones have a wide variety of uses in the dental industry including use as denture adhesive compositions (WO93/14737); non substantive neutral films (US 5,032,387) and rubber materials for taking impressions (EP 822233). Furthermore it has long been

WO 02/34221

PCT/US00/29384

4

recognised that polysiloxanes can be used within oral care compositions to provide a smooth, very thin water repellent coating to the teeth where they provide a hydrophobic surface and are thereby able to prevent the formation of caries and staining (GB 686,429, WO 93/23009 and WO95/03776). It has also been shown that, whilst the polysiloxane coating remains in place, it is able to act as a slow release reservoir for lipid soluble actives eg anti-bacterial agents (US 5,422,098). However, polysiloxanes themselves adhere to the teeth for only a short period of time so attempts have been made to enhance the substantivity by modifying the silicone oil for example by use of quaternised tertiary cyclic amines (GB 789,851); quaternary ammonium groups (US 4,161,518) and aminoalkyl groups in conjunction with a lipophilic actives (EP 0,528,457). The initial work has been further extended with the applications WO 96/19190, WO 96/19191, WO 96/19192, and WO 96/19563 which disclose alkyl, alkoxy-and aminoalkyl- dimethicone copolyol oral compositions for use on teeth or acrylic surfaces of dentures comprising a wide range of dental actives. These compositions combine efficacy with substantivity, in-use performance characteristics and good cleaning properties. Furthermore, US 5,057,307, US 5,057,309 and US 5,733,529 disclose gels comprising a non-ionic surfactant, a coating material which is insoluble in that surfactant preferably polysiloxane polymers with a viscosity up to 50 million cps, viscosifiers, preferably cellulose ethers, and oral care actives such as stannous fluoride. Finally copending applications PCT/US99/15890 and PCT/US99/15891 disclose oral care compositions comprising an organosiloxane resin in combination with a volatile carrier capable of solubilising the resin and an oral care active for preparing compositions which harden on the surface of the oral cavity. Whilst the compositions and disclosures of the prior art provide useful teaching for use of polysiloxanes in oral care compositions the approaches still have limitations. Overall there is no one composition which offers the combination of substantive and long term delivery of an oral care substance or active ingredient in conjunction with a product which is a non-drying composition which is easily applied to all surfaces of the oral cavity and which feels comfortable on the oral cavity surfaces, and which is able to be used for self treatment / home use and which is easy to remove.

WO 02/34221

PCT/US00/29384

5

Adhesive silicone systems are widely known including those which comprise a mixture of silicone gums with silicone resins in conjunction with a curing agent (eg catalysed condensation reactions, heating etc) and which are commonly referred to as pressure sensitive adhesives. Disclosures of such systems in the art include US 4016328, US 3,929,704, US 2,814,601, US2,736,721, and CA 2085696. Such systems themselves are not suitable for home use in the oral cavity due to the harsh curing conditions that are required. However, attempts have been disclosed in the art to modify these systems such that their substantivity can be exploited in personal care products. Applications in this area include WO 93/17660, WO 98/16196, WO 97/17058 and WO 97/17059 which disclose the use of silicone resin : gum blends with volatile solvents in cosmetic compositions; WO 92/08439, US 4,906,459, US 4,902,499, WO 92/10161 and WO 92/10162 which disclose the use of silicone resin/gum/fluid blends in conjunction with surfactants as hair conditioning products; WO 00/06100, WO00/06107 which disclose the use of silicone resins in hair hold compositions; and GB 2,289,686 and US 5,523,017 which disclose translucent silicone emulsion systems for use in personal care products. Whilst the teachings of the prior art do provide useful advances in the use of silicone compositions in personal care products it does not sufficiently teach how to combine silicone gums, resins and fluids together to prepare non volatile, non hardening compositions which are substantive on the surface of the oral cavity and easily removed and which can optionally also be used for long term delivery of various oral care actives.

Surprisingly it has now been found that when a silicone resin is combined with a silicone gum and a non volatile polydimethylsiloxane fluid a composition is formed which can be readily applied to all surfaces of the oral cavity and which remains substantive on those surfaces. In addition, when oral care actives are included in these compositions the composition can be used to deliver sustained release of a wide range of oral care actives to the oral cavity throughout the wear duration. Furthermore because the composition comprises no volatile solvents it remains fluid on the teeth such that it is both particularly effective at delivering therapeutic agents interproximally, subgingivally and into certain periodontal pockets and furthermore retains consumer preferred aesthetics since the

WO 02/34221

PCT/US00/29384

6

product does not form a hard coating on the surface of the teeth. Finally, because the film remains fluid it is easily removed by simple brushing and is therefore ideal for self administration by consumers. The invention can be further enhanced by optionally formulating it as a water in silicone emulsion wherein water soluble oral care actives can be dispersed within the water phase.

Without wishing to be bound by theory it is believed that the gum /resin mix creates a hydrophobic surface on the hard and soft tissues of the oral cavity which is able to both prevent build up of plaque and / or deliver oral care actives in a sustained manner. Furthermore it is believed that addition within the composition of the low viscosity fluid facilitates rapid wetting of surfaces of the composition which both aids spreading of the compositions onto the surfaces of the oral cavity and also facilitates the manufacturing process. Finally it is believed if such a system is a water in silicone emulsion that, over time, the water phase gains weight as a result of the osmosis of water from the saliva into the internal water phase. This is believed to further enhance the substantivity of the composition to the surfaces of the oral cavity.

It is an object of the present invention to provide a substantive coating for the teeth which has acceptable mouth feel properties and which can prophylactically or therapeutically treat the surfaces of the oral cavity including by sustained release of an oral care active. Furthermore it is an object of the present invention to provide a substantive film for application to the oral tissues which does not dry over time and thus is easy to remove such that the film can be easily self administered by consumers.

These, and other objects of this invention, will become apparent in light of the following disclosure.

Summary of the Invention

WO 02/34221

PCT/US00/29384

7

According to a first aspect the present invention relates to a non volatile composition that comprises:

- i) from about 0.5% to about 60%, by weight, of a silicone resin;
- ii) from about 0.1% to about 30%, by weight, of a silicone gum;
- iii) from about 0.1% to about 95%, by weight, of a non volatile polydimethylsiloxane fluid which has a viscosity from about 1cStk to about 1000cStk; and
- iv) from about 0.01% to about 50%, by weight, of an oral care active selected from teeth colour modifying substances, anti-tartar agents, anti-plaque agents, fluoride ion sources, anti-microbial agents, nutrients, antioxidants, H-2 antagonists, analgesics, anti-viral agents, mucosally absorbed pharmacological agents and mixtures thereof.

According to a second aspect the present invention relates to use of a non volatile oral care silicone composition in the oral cavity to treat the hard and soft tissue surfaces wherein the composition comprises:

- i) from about 0.5% to about 60%, by weight, of a silicone resin;
- ii) from about 0.1% to about 30%, by weight of a silicone gum;
- iii) from about 0.1% to about 95%, by weight, of a non volatile polydimethylsiloxane fluid which has a viscosity from about 1cStk to about 1000cStk.

According to a third aspect the present invention relates to a non volatile composition that comprises:

WO 02/34221

PCT/US00/29384

8

- i) from about 0.1% to about 30%, by weight, of a methyl substituted polyorganosiloxane gum with a viscosity of greater than 500,000 cStk;
- ii) an M:Q polyorganosiloxane resin wherein the M:Q ratio is in the range of 0.6-0.7;
- iii) a non volatile polydimethylsiloxane fluid which has a viscosity from about 5cStk to about 400cStk; and

wherein the weight ratio of polyorganosiloxane resin to polyorganosiloxane gum is in the range of from about 1:1 to about 7:1, wherein the weight ratio of polydimethylsiloxane fluid to polyorganosiloxane gum is in the range of from about 2:1 to about 8:1 and wherein the viscosity of the final composition is in the range of from about 1Pa.s to about 1000Pa.s.

Detailed Description of the Invention

All percentages and ratios used herein are by weight of the total composition and all measurements made are at 25°C, unless otherwise designated. Unless otherwise indicated all percentages, ratios and levels of ingredients referred to herein are based on the actual amount of the ingredient, and do not include solvent, fillers or other materials which may be combined with the ingredient in commercially available products.

All publications cited herein are hereby incorporated by reference in their entirety, unless otherwise indicated.

The term "oral care active" as used herein refers to any composition which has a prophylactic, therapeutic or cosmetic benefit either directly within the oral cavity or which is absorbed via the oral cavity but which has its primary benefit elsewhere.

WO 02/34221

PCT/US00/29384

The term "treatment" as used herein refers to process of applying a substance to the oral cavity, wherein that substance may or may not comprise an oral care active, such that a prophylactic, therapeutic or cosmetic benefit is achieved.

The term "oral cavity" as referred to herein refers to the cavity from the lips to the epiglottis. The "hard tissues" comprise tissues such as the teeth and peridental support and the like and the "soft tissues" comprise tissues such as the gums, the tongue, the surfaces of the buccal cavity and the like. Within the scope of this application the hard and soft tissues of the oral cavity should also be considered to comprise any devices which are used therein for example dentures, partial dentures, braces and the like.

The term "substantive" as used herein is understood to mean that sufficient quantities of the composition are retained in the oral cavity such that they can be perceived by the consumer either visually or by feel after a certain time period has elapsed. A guide to the expected *in vivo* substantivity of the compositions herein can be measured by an *in vitro* method. The method comprises using standard pharmaceutical disintegration apparatus, Erweka model ZT3-2, modified for gel applications. Briefly, a 50 μ m film of bulk composition is formed on a glass microscope slide using a draw down bar. The slide with applied composition is continually dipped in and out of test solution (artificial saliva, 35°C) over time; the weight of film is recorded at regular time intervals. Substantive compositions are defined as those retaining at least 10%, preferably 20% and more preferably 50% of their original wet weight after 2 hours exposure to solution has elapsed, preferably after 4 hours has elapsed and more preferably after 6 hours has elapsed.

The term "safe and effective amount" as used herein means an amount of a compound, component, or composition sufficient to significantly induce a positive benefit but low enough to avoid serious side effects, i.e. to provide a reasonable benefit to risk ratio, within the scope of sound medical judgement.

The term "non volatile" as used herein means that the material referred to exhibits very low or no significant vapour pressure at ambient conditions, as well known and understood in the art. Non-volatile material will also generally have a boiling point at one atmosphere pressure of at least 200°C, preferably 275°C, and more preferably at least 300°C. Furthermore this term means that the compositions comprise less than 10%,

WO 02/34221

PCT/US00/29384

10

preferably less than 5% and more preferably less than 2%, by weight, of a volatile material. As defined herein a volatile material is any material with a boiling point at one atmosphere of less than 200°C.

Viscosities are measured using standard Brookfield viscometer techniques at room temperature which are known to those skilled in the art. The viscosities of the final products were measured at 25°C using a Brookfield viscometer (model DV-II) using Spindle D at 10 rpm. Three readings were recorded at 1 min intervals, the average being taken as the viscosity measure of the sample.

Active and other ingredients useful herein may be categorised or described herein by their cosmetic and/or therapeutic benefit or their postulated mode of action. However, it is to be understood that the active and other ingredients useful herein can in some instances provide more than one cosmetic and/or therapeutic benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated application or applications listed.

General background material on silicones including sections discussing silicone fluids, gums and resins, as well as manufacture of silicones, can be found in Encyclopaedia of Polymer Science and Engineering, Volume 15, Second Edition, pp204-308, John Wiley & Sons Inc 1989 and Chemistry and Technology of Silicones, Walter Noll, Academic Press Inc, (Harcourt Brace Jovanovich, Publishers, New York), 1968, pp282-287 and 409-426, both incorporated herein by reference.

The elements of these compositions are described in more detail below.

Silicone Resins

Compositions for use in the present invention comprise from about 0.5% to about 60%, preferably from about 2% to about 50%, more preferably from about 10% to about 40% and most preferably from about 15% to about 25%, by weight, of a silicone resin.

Silicone resins as referred to herein are highly crosslinked polymeric siloxane systems. The crosslinking is introduced through the incorporation of tri-functional and tetra-

WO 02/34221

PCT/US00/29384

11

functional silanes with mono-functional or di-functional, or both, silanes during manufacture of the silicone resin. As is well understood in the art, the degree of crosslinking that is required in order to result in a silicone resin will vary according to the specific silane units incorporated into the silicone resin. In general, silicone materials which have a sufficient level of trifunctional and tetrafunctional siloxane monomer units (and hence a sufficient level of crosslinking) such that they dry down to a rigid or hard film are considered to be silicone resins. The ratio of oxygen atoms to silicone atoms is indicative of the level of crosslinking in a particular silicone material. Silicone materials which have at least about 1:1 oxygen atom per silicone atom will generally be silicone resins herein. Preferably, the ratio of oxygen: silicone atoms is at least about 1.2:1.0. Typical silanes used in the manufacture of silicone resins are the monomethyl, dimethyl, monophenyl, diphenyl, methylphenyl, monovinyl, and methylvinyl-chlorosilanes and tetrachlorosilanes. Preferred resins are the methyl, ethyl or phenyl substituted silicone resins. Commercially available silicone resins will generally be supplied in an unhardened form either as a powder or in a low viscosity volatile or, preferably non-volatile silicone fluid. It is preferred for use herein that the silicone resins are supplied as a powder or as a resin blend with a non volatile fluid.

Silicone resins can conveniently be identified according to a shorthand nomenclature system well known to those skilled in the art as the "MDTQ" nomenclature. Under this system, the silicone is described according to the presence of various siloxane monomer units which make up the silicone. Briefly, the symbol M denotes the mono-functional unit $((\text{CH}_3)_3\text{SiO})_{0.5}$; D denoted the di-functional unit $(\text{CH}_3)_2\text{SiO}$; T denotes the tri-functional unit $((\text{CH}_3)_3\text{SiO})_{1.5}$; and Q denoted the quadra- or tetra-functional unit SiO_2 . Note that a small amount of up to about 5% of silanol or alkoxy functionality may also be present in the resin structure as a result of processing. Primes of the unit symbols eg M', D', T', Q', denote substituents other than methyl, and must be specifically defined for each occurrence. Typical alternate substituents include groups such as vinyl, phenyl, amino, hydroxyl, etc. The molar ratios of the various units, either in terms of subscripts to the symbols indicating the total number of each type of unit in the silicone, or an average thereof, or as specifically indicated ratios in combination with molecular weight, complete the description of the silicone material under the "MDTQ" system. Higher

WO 02/34221

PCT/US00/29384

12

relative amounts of T, Q, T', Q' to D, D', M, M' in a silicone resin is indicative of higher levels of crosslinking. As discussed before however, the overall level of crosslinking can also be indicated by the oxygen to silicone ratio.

The silicone resins preferred for use herein are MQ, MT, MTQ, and MDTQ resins; such MQ resins are disclosed in US Patent 5,330,747, Krysik issued July 19 1994. Thus the preferred silicone substituent is methyl. Especially preferred are MQ resins wherein the M:Q ratio is from about 0.4 to about 0.8, preferably from about 0.6 to about 0.7. The preferred silicone resins are solid at about 25°C and the average molecular weight from about 1,000 to about 10,000. The preferred resins are soluble in organic solvents such as toluene, xylene, isoparaffins and cyclosiloxanes and mixtures thereof. Organosiloxane resins such as these are commercially available, for example, SR 1000 and GE 1170-002, GE SS4230 and SS4267 from the General Electric Company and Wacker 803 and 804 available from Wacker Silicones corporation of Adrian, Michigan, US.

Silicone Gums

Compositions for use in the present invention comprise from about 0.1% to about 30%, preferably from about 1% to about 20%, more preferably from about 1% to about 10% and most preferably from about 2% to about 7%, by weight, of a silicone gum.

"Silicone gum" materials denote high molecular weight polydiorganosiloxanes having a viscosity at 25°C of from about 500,000cStk up to about 50,000,000cStk. The viscosity of the material can be measured by means of a glass capillary viscometer as set forth in Dow Corning Corporate Test Method CTM004, July 20, 1970. In addition silicone gums for use herein are considered to be polydiorganosiloxanes with an average molecular weight of greater than 500,000.


Silicone gums useful herein are described by Petrarch and others including US Pat No 4,152,416 and Noll, Walter Chemistry and Technology of Silicones New York Academic Press 1968. Also describing silicone gums are various General Electric Silicone Rubber Product Data Sheets. All of these described references are incorporated herein by reference.

WO 02/34221

PCT/US00/29384


13

The polysiloxane gums most suitable for use herein include those represented by the general formula (I):



wherein each R independently is substituted or unsubstituted aliphatic (eg alkyl or alkenyl), aryl, alkoxy, alkylaryl, alkoxy, alkylamino (eg alkyl or alkenyl amino groups), hydroxy, or hydrogen or combinations thereof; and x is an integer sufficient such that the gum has the desired viscosity.

The polysiloxane gum for use herein can be linear or cyclic. Linear polysiloxanes are exemplified by Formula (I) above. Branched chain can also be used. Cyclic polysiloxanes include those represented by Formula (II):



wherein R is as defined above and n is an integer sufficiently high such that the gum has the desired viscosity, preferably from about 10 to about 100.

The substituents on the siloxane chain R may have any structure as long as the resulting polysiloxanes are hydrophobic, are neither irritating, toxic nor otherwise harmful when applied to human teeth, are capable of being deposited on human teeth, are compatible with the other components of the composition and are chemically stable under normal use and storage conditions.

Preferred alkyl and alkenyl substituents include C1 -C5 alkyls and alkenyls, more preferably from C1 - C4, most preferably from C1-C2. The aliphatic portions of other alkyl-, alkenyl-, or alkynyl- containing groups (such as alkoxy, alkylaryl and alkamino) can be straight or branched chains and preferably have from 1 to 5 carbon atoms, more

WO 02/34221

PCT/US00/29384

14

preferably from 1 to 4 carbon atoms, even more preferably from 1 to 3 carbon atoms and most preferably from 1 to 2 carbon atoms. As discussed above the R substituents hereof can also contain amino functionalities eg alkamino groups which can be primary, secondary, tertiary amines or quaternary ammonium. These include mono, di, tri-alkylamino and alkoxyamino groups wherein the aliphatic portion chain length is preferably as described above. The R substituents can also be substituted with other groups, such as halogens (eg chloride, fluoride and bromide) halogenated aliphatic or aryl groups and hydroxy (eg hydroxy substituted aliphatic groups). Suitable halogenated R groups could include for example tri-halogenated (preferably fluorine) alkyl groups such as $R_1-C(F)_3$, wherein R_1 is C1-C3 alkyl. Preferred are methyl substituted polyorganosiloxane gums and methyl substituted polyorganosilanol gums.

Aryl containing substituents contain alicyclic and heterocyclic five and six membered aryl rings, and substituents containing fused five or six membered rings. The aryl rings themselves can be substituted or unsubstituted. Substituents include aliphatic substituents and can also include alkoxy substituents, acyl substituents, ketones, halogens (eg chloride, fluoride and bromide), amines etc. Exemplary aryl-containing groups include substituted and unsubstituted alkyl or alkenyl substituents eg allylphenyl, methyl phenyl, ethyl phenyl, vinyl phenyls such as styrenyl, and phenyl alkynes (eg phenyl C2-C4 alkynes). Heterocyclic aryl groups include substituents derived from furan, imadazole, pyrrole, pyridine etc. Fused aryl ring substituents include, for example, naphthalene, coumarin and purine.

Specific examples of preferred siloxane gums include polydimethylsiloxane, methylvinylsiloxane, copolymer, poly(dimethylsiloxane, diphenyl, methylvinylsiloxane copolymer and mixtures thereof. The safety of polydimethylsiloxanes or use in these various products is well documented. See Rowe et al., Journal of Industrial Hygiene, 30:332-352 (1948). See also Calandra et al., "ACS Polymer Preprints," 17:1-4 (1976) and Kennedy et al., J. Toxicol. & Environmental Health, 1:909-920 (1976). A highly preferred silicone gum is SE30 from General Electric.

For compositions for use herein it is highly preferred that the weight ratio between the silicone resin and the high molecular weight silicone gum is in the range of from about

WO 02/34221

PCT/US00/29384

15

0.1:1 to about 9:1, preferably from about 1:1 to about 7:1 and more preferably from about 1:1 to about 5:1.

Silicone Fluids

Compositions for use herein also comprise from about 0.1% to about 95%, preferably from about 5% to about 90%, more preferably from about 10% to about 85%, by weight of a non volatile polysiloxane fluid with a viscosity, at 25°C, of from about 1cStk to about 1000cStk, preferably from about 2cStk to about 500cStk and more preferably from about 5cStk to about 400cStk.

As for the gums, polysiloxane fluids for use herein can be linear or cyclic. They can be substituted with a wide variety of substituents. Any substituent already described above for the siloxane gums should also be considered to be useful as a substituent of the polysiloxane fluids. Preferred alkyl and alkenyl substituents include C1 -C5 alkyls and alkenyls, more preferably from C1 - C4, most preferably from C1-C2 and preferred aryl substituents are alicyclic and heterocyclic five and six membered aryl rings. Highly preferred substituents include methyl, ethyl and phenyl substituents. Methyl is the most preferred substituent.

Suitable polysiloxane fluids include linear polysiloxane polymers such as dimethicone and other low viscosity analogues of the polysiloxane materials, preferably having a viscosity at 25°C of 200cStk or less and cyclomethicone, and other cyclic siloxanes having for example a viscosity at 25°C of 200cStk or less. Commercial examples of materials that are suitable for use herein include DC200 series fluids from Dow Corning and the AK Fluid series from Wacker Silicones.

It is preferred that for compositions for use herein that the weight ratio between the low viscosity polysiloxane fluid and the high viscosity polysiloxane gum is in the range of from about 0.1:1 to about 20:1, preferably from about 1:1 to about 10:1 and more preferably from about 2:1 to 8:1 and even more preferably from about 2:1 to about 5:1.

Oral Care Actives

WO 02/34221

PCT/US00/29384

16

According to a first aspect of the invention the compositions herein comprise from about 0.01% to about 50%, preferably from about 0.01% to about 20%, more preferably from about 0.01% to about 10%, by weight, of an oral care active selected from teeth colour modifying substances, anti-tartar agents, anti-plaque agents, fluoride ion sources, anti-microbial agents, nutrients, antioxidants, H-2 antagonists, analgesics, anti-viral agents, mucosally absorbed pharmacological agents and mixtures thereof. The oral care actives preferably contain an active at a level where upon directed use, the benefit sought by the wearer is promoted without detriment to the oral surface to which it is applied.

Oral care compositions or substances of the present invention may include many of the actives previously discussed in the art. The following is a non-limiting list of oral care actives that may be used in the present invention:

1. Teeth Colour Modifying Substances Teeth colour modifying substances may be considered among the oral care actives useful in the present invention. These substance are suitable for modifying the colour of the teeth to satisfy the consumer. These substances could be particles that when applied on the tooth surface modify that surface in terms of absorption and, or reflection of light. Such particles provide an appearance benefit when a film containing such particles is applied over the surfaces of a tooth or teeth. This benefit may last to the point wherein the film has eroded, or been removed, presenting for example a mottled or uniform looking tooth surface.

Particles most useful in the present invention include pigments and colourants routinely used in the cosmetic arts. There are no specific limitations as to the pigment and, or colourant used in compositions of the present invention other than the limitation of the effect it has on the light source upon the teeth surfaces. Pigments and colourants include inorganic white pigments, inorganic coloured pigments, pearling agents, filler powders and the like; see Japanese Published Patent Application Kokai No 9 [1997]-100215, published April 15, 1997, incorporated herein by reference. Specific examples are selected from the group consisting of talc, mica, magnesium carbonate, calcium carbonate, magnesium silicate, aluminium magnesium carbonate, silica, titanium dioxide, zinc oxide, red iron oxide, brown iron oxide, yellow iron oxide, black iron oxide, ferric ammonium ferrocyanide, manganese violet, ultramarine,

WO 02/34221

PCT/US00/29384

17

nylon powder, polyethylene powder, methacrylate powder, polystyrene powder, silk powder, crystalline cellulose, starch, titanated mica, iron oxide titanated mica, bismuth oxychloride, and mixtures thereof. Most preferred are those selected from the group consisting of titanium dioxide, bismuth oxychloride, zinc oxide and mixtures thereof. Pigments that are generally recognised as safe, and are listed in the CTFA Cosmetic Ingredient Handbook, 3rd Edition, Cosmetic and Fragrances Association Inc., Washington DC (1982), incorporated herein by reference.

The pigments are typically used as opacifiers and colourants. These pigments can be used as treated particles, or as the raw pigments themselves. Typical pigment levels are selected for the particular impact that is desirable by the consumer. For example, for teeth that are particularly dark or stained one would typically use pigments in sufficient amount to lighten the teeth. On the other hand, where individual teeth or spots on the teeth are lighter than other teeth, pigments to darken the teeth may be useful. The levels of pigments and colourants are generally used in the range of about 0.05% to about 20%, preferably from about 0.1% to about 15% and most preferably from about 0.25% to about 10%, by weight, of the composition. It is highly preferred that when a composition for use herein comprises a pigment it additionally comprises a further oral care active.

Compositions for use herein may also comprise materials that remove or bleach intrinsic or extrinsic stains on or in tooth surfaces. Such substances are selected from the group consisting of the peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulphates, and combinations thereof. Suitable peroxide compounds include hydrogen peroxide, urea peroxide, calcium peroxide, carbamide peroxide and mixtures thereof. Most preferred is carbamide peroxide. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite and potassium chlorite. Additional bleaching substances may be hypochlorite, and chlorine dioxide. The preferred chlorite is sodium chlorite. A preferred percarbonate is sodium percarbonate. Preferred persulphates are oxones. The level of these substances is dependent on the available oxygen or chlorine respectively that the molecule is capable of providing to bleach the stain. This level is generally used in

WO 02/34221

PCT/US00/29384

18

compositions of the present invention at levels from about 0.1% to about 35%, preferably from about 1% to about 25% and most preferably from about 5% to about 10% of the composition.

2. Anti-tartar Agents Anti-tartar agents known for use in dental care products include phosphate Phosphates include pyrophosphates, polyphosphates, polyphosphonates and mixtures thereof. Pyrophosphates are among the best known for use in dental care products but polyphosphates are also considered to be highly useful in the compositions of the present invention. The pyrophosphate salts useful in the present compositions include the dialkali metal pyrophosphate salts, tetra-alkali metal pyrophosphate salts and mixtures thereof. Disodium dihydrogen pyrophosphate ($\text{Na}_2\text{H}_2\text{P}_2\text{O}_7$), tetrasodium pyrophosphate ($\text{Na}_4\text{P}_2\text{O}_7$), and tetrapotassium pyrophosphate ($\text{K}_4\text{P}_2\text{O}_7$) and mixtures thereof, in their unhydrated as well as hydrated forms are the preferred species. While any of the above mentioned pyrophosphate salts may be used, tetrasodium pyrophosphate salt is preferred. Sodium polyphosphate and triethanolamine polyphosphates, for example, are preferred.

The pyrophosphate salts are described in more detail in Kirk and Othermer, Encyclopediadia of Chemical Technology, 3rd Edition, Volume 17, Wiley Interscience Publishers (1982). Additional anticalculus agents include pyrophosphates or polyphosphates disclosed in US Patent No 4,590,066 issued to Parran and Sakkab on May 20, 1986; polyacrylates and other polycarboxylates such as those disclosed in US Patent No 3,429,963 issued to Shedlovsky on February 25, 1969 and US Patent No 4,304,766 issued to Chang on December 8, 1981; and US Patent No 4,661,341 issued to Benedict and Sunberg on April 28, 1987; polyepoxysuccinates such as those disclosed in US Patnet No 4,846,650 issued to Bendict, Bush and Sunberg on July 11, 1989; ethylenediaminetetraacetic acid as disclosed in British Patent No 490,384 date February 15, 1937; nitrilotriacetic acid and related compounds as disclosed in US Patent No 3,678,154 issued to Widder and Briner on July 18, 1972; polyphosphonates as disclosed in US Patent No 3,737,533 issued to Francis on June 5, 1973; US Patnet No 3,988,443 issued to Ploger, Schmidt-Dunker and Gloxhuber on October 26, 1976 and US Patent No 4,877,603 issued to Degenhardt and Kozikowski on October 31,

WO 02/34221

PCT/US00/29384

19

1989. Anticalculus phosphates include potassium and sodium pyrophosphates; sodium tripolyphosphate; diphosphonates such as ethane-1-hydroxy-1, 1-diphosphonate, 1-azacycloheptane-1, 1-diphosphonate, and linear alkyl disphosphonates; linear carboxylic acids; and sodium zinc citrate and other soluble zinc salts.

Polyphosphates preferred are those having a chain length of three or more, especially those with a chain length of around four or more phosphate molecules including tetrapolyphosphate and hexametaphosphate, among others. Polyphosphates larger than tetrapolyphosphate usually occur as amorphous glassy materials. Preferred in this invention are the linear "glassy" polyphosphates having the formula:



wherein X is sodium, potassium, or hydrogen and n averages from about 6 to about 125. Most preferred is a particulate sodium polyphosphate with an average chain length of from about 10 to about 30, preferably from about 15 to 25, more preferably from about 21 to about 23. Such polyphosphates are manufactured by FMC Corporation and are commercially known as Sodaphos ($n \approx 6$), Hexaphos ($n \approx 13$), and Glass H ($n \approx 21$). Hexaphos and Glass H are preferred with Glass H being the most preferred polyphosphate. These polyphosphates may be used alone or in a combination thereof.

Agents that may be used in place of, or in combination with, the pyrophosphate salt include such known materials as synthetic anionic polymers including polyacrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (eg Gantrez), as described, for example in US Patent 4,627,977 to Gaffer et al; as well as eg polyamino propane sulphonic acid (AMPS), zinc citrate trihydrate, polyphosphates (eg tripolyphosphate; hexametaphosphate), diphosphonates (eg EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids) and mixtures thereof.

3. Anti-Plaque Agents Anti-plaque agents are any substances which inhibit the accumulation of bacterial deposits on the surfaces of the oral cavity. Examples include xylitol and other anti-microbial agents.

WO 02/34221

PCT/US00/29384

20

4. Fluoride Ion Source Fluoride ion sources are well known for use in oral care compositions as anticaries agents. Fluoride ions are contained in a number of oral care compositions for this purpose, particularly toothpastes. Patents disclosing such toothpastes include US Patent No 3,538,230, Nov 3, 1970 issued to Pader et al; US Patent No 3,689,637, September 5th 1972 to Pader; US Patent No 3,711,604, January 16 1973 to Colodney et al; US Patent No 3,911,104 October 7, 1975 to Harrison; US Patent No 3,935,306, January 26, 1976 to Roberts et al; and US Patent NO 4,040,858 August 9, 1977 to Wasson.

Application of fluoride ions to dental enamel serves to protect teeth against decay. A wide variety of fluoride ion yielding materials can be employed as sources of soluble fluoride in the present compositions. Examples of suitable fluoride ion yielding materials are found in US Patent No 3,535,421, October 20, 1970 issued to Briner et al and US Patent No 3,678,154 July 18, 1972 issued to Widder et al. Preferred fluoride ion sources for use herein include sodium fluoride, potassium fluoride, stannous fluoride, ammonium fluoride and mixtures thereof. Sodium fluoride is particularly preferred. Preferably the present composition provide from about 50ppm to about 10,000ppm, more preferably from about 100ppm to about 3000ppm of fluoride ions in the compositions that contact dental surfaces when used with the delivery system of the present invention.

5. Anti Microbial Agents Antimicrobial agents can also be present in the oral care compositions or substances of the present invention. Such agents may include, but are not limited to, 5-chloro-2-(2, 4-dichlorophenoxy)-phenol, commonly referred to as triclosan, and described in the Merck Index, 11th Edition, (1989), pp1529 (entry no 9573) in US Patent No 3,506,720, and in European Patent Application No 0,251,591 of Beecham Group, Plc, published January 7th, 1988; phthalic acid and its salts including, but not limited to those disclosed in US Patent 4,994,262 published February 19th, 1991, preferably magnesium mono-potassium phthalate, chlorhexidine (Merck Index, no 2090); alexidine (Merck Index, no 222); hexetidine (Merck Index, no 4624); sanguinarine (Merck Index, no 8320); benzalkonium chloride (Merck Index, no 1066); salicylanilide (Merck Index, no 8299); domiphen bromide (Merck Index, no 3411);

WO 02/34221

PCT/US00/29384

21

cetylpyridinium chloride (CPC) (Merck Index, no 2024); tetradecylpyridinium chloride (TPC); N-tetradecyl-4-ethylpyridinium chloride (TDEPC); octenifine; delmopinol; octapinol; and other piperidine derivatives; nicin preparations; zinc/stannous ion agents; antibiotics such as augmentin, amoxicilline, tetracycline, doxycycline, minocycline, and metronidazole; and analogues and salts of the above; essential oils including thymol, geraniol, carvacrol, citral, hinokitiol, eucalyptol, catechol (particularly 4-allyl catechol) and mixtures thereof; methyl salicylate; hydrogen peroxide; metal salts of chlorite and mixtures of all of the above.

6. Nutrients Nutrients may improve the condition of the oral cavity and can be include in the oral care compositions or substances of the present invention. Nutrients include minerals, vitamins, oral nutritional supplements, enteral nutritional supplements, herbal supplements, natural extracts and mixtures thereof.

Minerals that can be included with the compositions of the present invention include calcium, phosphorus, fluoride, zinc, manganese, potassium and mixtures thereof. These minerals are disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluwer Company, St Louis, Mo., ©1997, pp10-17.

Vitamins can be included with minerals or used separately. Vitamins include Vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, and mixtures thereof. Such vitamins are disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluwer Company, St Louis, Mo., ©1997, pp3-10.

Oral nutritional supplements include amino acids, lipotropics, fish oil, coenzyme Q10, and mixtures thereof, as disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluwer Company, St Louis, Mo., ©1997, pp54-54e. Amino acids include, but are not limited to L-tryptophane, L-lysine, methionine, threonine, levocarnitine or L-carnitine and mixtures thereof. Lipotropics include, but are not limited to choline, inositol, betaine, linoleic acid, linolenic acid and mixtures thereof. Fish oil contains large amounts of Omega-3 (N-3) polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid.

WO 02/34221

PCT/US00/29384

22

Entenal nutritional supplements include, but are not limited to, protein products, glucose polymers, corn oil, safflower oil, medium chain triglycerides as disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluwer Company, St Louis, Mo., ©1997, pp55-57.

7. Antioxidants Antioxidants are generally recognised as useful in compositions such as those of the present invention. Antioxidants are disclosed in texts such as Cadenas and Packer, The Handbook of Antioxidants, © 1996 by Marel Dekker, Inc. Antioxidants that may be included in the oral care compositions of the present invention include, but are not limited to, Vitamin E, ascorbic acid, Uric acid, carotenoids, Vitamin A, flavenoids and polyphenols, herbal antioxidants, melatonin, aminoindoles, lipoic acids and mixtures thereof.
8. H-2 Antagonists Histamine-2 (H-2) receptor antagonist compounds (H-2 antagonists) may be used in the oral care compositions of the present invention. As used herein, selective H-2 antagonists are compounds that block H-2 receptors, but do not have meaningful activity in blocking histamine -1 (H-1) receptors. Selective H-2 antagonists stimulate the contraction of smooth muscle from various organs, such as the gut and bronchi; this effect can be suppressed by low concentrations of mepyramine - a typical antihistaminic drug. The pharmacological receptors involved in these mepyramine-sensitive histamine responses have been defined as H-1 receptors (Ash, A.S.F & Schild H.O, Brit J Pharmacol Chem 1966, Vol 27, p427). Histamine also stimulates the secretion of acid by the stomach (Loew ER & Chickering O, Proc Soc Exp Biol Med, 1941, Vol 48, p65), increases the heart rate (Trendelenburg U J. Pharmacol 1960, Vol 130 p450) and inhibits contractions in the rat uterus (Dews PB & Graham JDP, Brit J. Pharmacol Chem, 1946, Vol 1, p278); these actions cannot be antagonised by mepyramine and related drugs. The H-2 antagonists useful in the oral care compositions or substances are those that blockade the receptors involved in mepyramine insensitive, non H-1 (H-2), histamine responses and do not blockade the receptors involved in mepyramine-sensitive histamine responses.

Selective H-2 antagonists are those compounds found to be H-2 antagonists through their performance in classical pre-clinical screening tests for H-2 antagonist function.


WO 02/34221

PCT/US00/29384

23

Selective H-2 antagonists are identified as compounds which can be demonstrated to function as competitive or non-competitive inhibitors of histamine mediated effects in those screening models specifically dependent upon H-2 receptor function, but to lack significant histamine antagonist activity in those screening models dependent upon H-1 receptor function. Specifically, this includes compounds that would be classified as described by Black JW, Duncan WAM, Durant CJ, Ganelline CR & Parsons EM, "Definitions and Antagonism of Histamine H2-Receptors", Nature 1972, vol 236 pp385-390, as H-2 antagonists if assessed as described by Black through testing with the guinea pig spontaneously beating right atria in vitro assay and the rat gastric acid secretion in vivo assay, but shown to lack insignificant H-1 antagonist activity relative to H-2 antagonist activity, if assessed as described by Black with either the guinea pig ileum contraction in vitro assay or the rat stomach muscle contraction in vivo assay. Preferably selective H-2 antagonists demonstrate no significant H-1 activity at reasonable dosage levels in the above H-1 assays. Typical reasonable dosage level is the lowest dosage level at which 90% inhibition of histamine, preferably 99% inhibition of histamine, is achieved in the above H-2 assays.

Selective H-2 antagonists include compounds meeting the above criteria which are disclosed in US Patents 5,294,433 and 5,364,616 Singer et al., issued 15th March 1994 and 15th November 1994 respectively and assigned to Procter & Gamble, wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidiein, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728 and HB-408.4. Particularly preferred is cimetidine (SKF-92334), N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine:



WO 02/34221

PCT/US00/29384

24

Cimetidine is also disclosed in the Merck Index, 11th editions (1989), p354 (entry no 2279), and Physicians' Desk Reference, 46th edition (1992), p2228. Related preferred H-2 antagonists include burimamide and metiamide.

9. Analgesics Anti-pain or desensitising agents can also be present in the oral care compositions or substances of the present invention. Such agents may include, but are not limited to, strontium chloride, potassium nitrate, natural herbs such as gall nut, Asarum, Cubebin, Galanga, scutellaria, Liangmianzhen, Baizhi, etc. Analgesics also include the anti-inflammatory agents. Such agents may include, but are not limited to, non-steroidal anti-inflammatory agents of NSAIDs, such as ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, aspirin, ketoprofen, piroxicam and meclofenamic acid. Use of NSAIDs such as Ketorolac are claimed in US Patent 5,626,838, issued May 6th, 1997. Disclosed therein are methods of preventing and, or treating primary and reoccurring squamous cell carcinoma of the oral cavity or oropharynx by topical administration to the oral cavity or oropharynx an effective amount of an NSAID.
10. Anti-Viral Agents Anti-viral actives useful in the present composition include any known actives that are routinely used to treat viral infections. Such anti-viral actives are disclosed in Drug Facts and Comparisons (Loose leaf drug information service), Wolters Kluwer Company, St. Louis, Mo, ©1997, pp402(a)-407(z), incorporated herein by reference in its entirety. Specific examples include anti-viral actives disclosed in US Patent 5,747,070 issued 5th May 1998 to Satyanarayana Majeti, incorporated herein by reference in its entirety. Said Patent discloses the use of stannous salts to control viruses. Stannous salts and other anti-viral actives are described in detail in Kirk and Othmer, Encyclopaedia of Chemical Technology, 3rd Edition, vol 23, Wiley Interscience Publishers (1982), pp42-71, incorporated herein by reference in its entirety. The stannous salts that may be used in the present invention would include organic stannous carboxylates and inorganic stannous halides. While stannous fluoride may be used, it is typically used only in combination with another stannous halide or one or more stannous carboxylates or another therapeutic agents.
11. Mucosally Absorbed Pharmacological Agents Antitussives are actives particularly useful for arresting uncontrollable fits of coughing. Antitussives useful in the present

WO 02/34221

PCT/US00/29384

25

invention include, but, are not restricted to, the group consisting of codeine, dextromethorphan, dextrophan, diphenhydramine, hydrocodone, noscapine, oxycodone, pentoxyverine, pholcodine and mixtures thereof. Of these antitussives, dextromethorphan is preferred. Safe and effective amounts of other cough/cold drug actives may be included in such dextromethorphan-containing compositions. Particularly useful are the actives that are suited for absorption through the mucosal tissues as described in J. G. Hardman, *The Pharmacologic Basis of Therapeutics*, Ninth Edition, McGraw-Hill, New York, 1995. Other actives which are absorbed through the mucosal membrane include antihistamines; non-sedating antihistamines; decongestants; expectorants; mucolytics, analgesic, antipyretic anti-inflammatory agents, local anesthetics and mixtures thereof. As such these actives may also be incorporated into compositions of the present invention.

Other Ingredients

In addition these oral care products can contain a variety of nonessential optional components suitable for rendering such compositions more acceptable. Such conventional optional ingredients are well known to those skilled in the art eg preservatives such as benzyl alcohol, methyl paraben, propyl paraben and imidiazolindinyl urea; cationic surfactants such as cetyl trimethylammonium chloride, lauryl trimethyl ammonium chloride, tricetyl methyl ammonium chloride and di(partially hydrogenated tallow) dimethylammonium chloride; thickeners and viscosity modifiers such as diethanolamide of long chain fatty acid (eg PEG 3 lauramide), block polymers of ethylene oxide and propylene oxide such as Pluronic F88 offered by BASF Wyandotte, sodium chloride, sodium sulphate, polyvinyl alcohol, and ethyl alcohol; pH adjusting agents and buffering agents such as citric acid, succinic acid, phosphoric acid, sodium hydroxide, sodium carbonate etc; sweetening agents; flavouring agents such as oil of peppermint, oil of sassafras, clove bud oil, peppermint, menthol, anethole, thymol, methylsalicylate, eucalyptol, cassia, 1- menthyl acetate, sage, eugenol, parsely oil, oxanone, oil of wintergreen, alpha-irisone, oil of spearmint, marjoram, lemon, orange, propenyl guaethol, cinnamon, and mixtures thereof; perfumes; dyes; and sequestering

WO 02/34221

PCT/US00/29384

26

agents such as disodium ethylenediamine tetraacetate. Such agents are generally used individually at a level of from about 0.001% to about 10%, preferably from about 0.5% to about 5.0%, by weight, of the composition.

Compositions for use herein comprise less than 10%, preferably less than 5% and more preferably less than 2%, by weight, of volatile solvents. As defined herein volatile solvents refer to any material, organic or silicone in origin, which has a boiling point of 200°C, or less, at one atmosphere pressure.

Furthermore compositions for use herein are intended to be used without the need for curing, either hot curing or cold curing. As such it is intended that compositions of the present invention are used alone and without any additional curing agent.

According to the third aspect of this invention the compositions have a viscosity of from about 1Pa.s to about 1000Pa.s. For all aspects of this invention it is preferred that the compositions have a viscosity of from about 2Pa.s to about 500Pa.s, preferably from about 5Pa.s to about 300Pa.s and more preferably from about 10Pa.s to about 250Pa.s.

Rheology Modifiers

The compositions of the present invention can optionally comprise a rheology modifier which inhibits settling and separation of components or control settling in a manner which facilitates re-dispersion and may control rheological flow properties. Suitable rheology modifiers herein include organo modified clays, silicas, cellulose polymers such as hydroxypropylmethyl cellulose, xanthum gum, carbomers, inorganic clay polymers, polycarboxylates, EO/PO block copolymers (poloaxomers) thickening silicas and mixtures thereof. The preferred organophilic clays comprise Quaternium-18 hectorite or Stearalkonium hectorate, such as Bentone 27 and 38 from Rheox, organoclay dispersion such as Bentone ISD Gel; or bentonites organo modified clays such as Bentone 34 from Rheox or the Claytone Series from Southern Clay Products; and mixtures thereof. The preferred silicas may be fumed silica such as the Aerosil series from Degussa or the Cab-o-Sil series from Cabot Corporation, silica gels such as the Sylodent or Sylox series from WR Grace & Co or precipitated silica such as Zeothix 265 from JM Huber Corporation. The rheology modifier is preferably present in the composition at a level of from about

WO 02/34221

PCT/US00/29384

27

0.1% to about 15%, preferably from about 0.5% to about 10%, and even more preferably from about 1% to about 3%, by weight, of the composition.

Carrier

Compositions for use herein can take a variety of forms for example single phase silicone systems, an emulsion system such as a water in silicone emulsion or an oil in silicone emulsion or a dispersion. The advantage of combining an additional phase into compositions of the present invention is that the additional phase can be used to solubilise additional ingredients for example oral care actives, which are not naturally soluble in silicone systems. It is highly preferred that the compositions for use herein are water in silicone emulsions, or water in silicone dispersion, wherein the internal water phase comprises from about 5% to about 95%, preferably from about 25% to about 75%, more preferably from about 30% to about 60%, by weight, of the final composition. Furthermore it is preferred that such a system comprises from about 0.001% to about 90%, preferably from about 5% to about 75%, even more preferably from about 10 % to about 60%, by weight, of water. Furthermore it is preferred that if the composition is a water in silicone emulsion or dispersion that the internal aqueous phase comprises rheology modifiers.

Preparation of Compositions

The compositions of the present invention are prepared by standard techniques well known to those skilled in the art. If the composition comprises more than one phase, in general the different phases will be prepared separately, with materials of similar phase partitioning being added in any order. The two phases will then be combined with vigorous stirring to form the multiphase system eg an emulsion or dispersion. Any ingredients in the formulation with high volatility, or which are susceptible to hydrolysis at high temperatures, will usually be added post mixing of the different phases with gentle stirring.

Method of Use

WO 02/34221

PCT/US00/29384

28

A second aspect of this invention relates to the use of a non volatile oral care silicone composition in the oral cavity to form a hydrophobic layer on the hard and soft tissue surfaces wherein the composition comprises:

- i) from about 0.5% to about 60%, by weight, of a silicone resin;
- ii) from about 0.1% to about 30%, by weight of a silicone gum;
- iii) from about 0.1% to about 95%, by weight, of a non volatile polysiloxane fluid which has a viscosity from about 1cStk to about 1000cStk.

Compositions of the present invention are applied to the surfaces of the oral cavity either by use of an applicator or by use of the finger. Compositions can either be applied to one or more particular areas of the oral cavity or broadly applied to the whole cavity. Due to the wetting properties of the compositions, once applied, they will rapidly spread to cover a wide area. As a result compositions can be used to coat hard to reach areas of the oral cavity such as interdental pockets, subgingival cavities and the like. Furthermore, as a result of the substantivity of the compositions herein they will remain in place on the surfaces of the oral cavity for at least 2 hours, preferably 4 hours, more preferably 6 hours and most preferably 8 hours. Compositions are then easily removed from the cavity by normal oral hygiene techniques such as brushing without damaged to the tissues of the oral cavity.

Examples

The following examples further illustrate the preferred embodiments within the scope of the present invention. These examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention as many variations of the invention are possible without departing from its spirit or scope. Unless otherwise indicated, all ingredients are expressed as a weight percentage of the composition.

Example 1:

WO 02/34221

PCT/US00/29384

29

INGREDIENT	% w/w
Silicone resin (SR1000; GE Silicones) ¹	30.00
Silicone gum (SE30; GE Silicones) ¹	10.00
Silicone fluid (DC200 350 cStk; Dow Corning) ²	60.00
TOTAL	100.00

Using an overhead mixer, slowly add silicone gum to pre-weighed silicone fluid. Once uniformly mixed, slowly add in resin under mixing until composition appears visually clear.

Example 2:

INGREDIENT	% w/w
Silicone resin (TMS 803, Wacker Chemicals) ³	32.00
Silicone gum/fluid blend (CF1251; GE Silicones) ¹	53.33
Silicone fluid (DC200 350 cStk; Dow Corning) ²	14.67
TOTAL	100.00

Using an overhead mixer, slowly add silicone resin to pre-weighed silicone fluid/gum blend till uniformly mixed and composition appears visually clear.

Example 3:

INGREDIENT	% w/w
Silicone resin (SR1000; GE Silicones) ¹	35.00
Silicone gum/fluid blend (CF1251; GE Silicones) ¹	64.70

WO 02/34221

PCT/US00/29384

30

Triclosan	0.30
TOTAL	100.00

Using an overhead mixer, slowly add silicone resin to pre-weighed silicone fluid/gum blend till uniformly mixed and composition appears visually clear.

Example 4:

INGREDIENT	% w/w
Silicone resin (SR1000; GE Silicones) ¹	19.82
Silicone gum/fluid blend (SF1236; GE Silicones) ¹	33.31
Silicone fluid (DC200 100 cStk; Dow Corning) ²	8.47
Water	28.30
Xylitol	10.00
Methyl/Propyl parabens	0.10
TOTAL	100.00

Using an overhead mixer, add silicone fluid to silicone gum/fluid blend. Slowly add silicone resin to pre-weighed silicone fluid/gum blend till uniformly mixed and composition appears visually clear. Separately, dissolve xylitol and parabens in water. Add into silicone premix under strong mixing.

Example 5:

INGREDIENT	% w/w
Silicone resin (SR1000; GE Silicones) ¹	20.00
Silicone gum/fluid blend (SF1236; GE Silicones) ¹	33.31
Silicone fluid (DC200 350 cStk; Dow Corning) ²	8.29

WO 02/34221

PCT/US00/29384

31

Triclosan	0.30
Water	28.00
Xylitol	10.00
Methyl/Propyl parabens	0.10
TOTAL	100.00

Using an overhead mixer, add silicone fluid to silicone gum/fluid blend. Slowly add silicone resin (with triclosan pre-dispersed therein) to pre-weighed silicone fluid/gum blend till uniformly mixed and composition appears visually clear. Separately, dissolve xylitol and parabens in water. Add into silicone premix under strong mixing.

Example 6:

INGREDIENT	% w/w
Silicone resin (SR1000; GE Silicones) ¹	10.00
Silicone gum/fluid blend (SF1236; GE Silicones) ¹	33.31
Silicone fluid (DC200 350 cStk; Dow Corning) ²	7.99
Triclosan	0.30
Water	30.00
Xylitol	10.00
Glycerin	8.00
Xanthan Gum (Ketrol 1000) ⁴	0.30
Methyl/Propyl parabens	0.10
TOTAL	100.00

Using an overhead mixer, add silicone fluid to silicone gum/fluid blend. Slowly add silicone resin (with triclosan pre-dispersed therein) to pre-weighed silicone fluid/gum blend till uniformly mixed and composition appears visually clear. Separately, dissolve xylitol and parabens in water. Add into silicone premix under strong mixing. Predisperse Xanthan gum in glycerin and add to bulk under strong mixing.

WO 02/34221

PCT/US00/29384

32

Example 7:

INGREDIENT	% w/w
Silicone resin (SR1000; GE Silicones) ¹	10.00
Silicone gum/fluid blend (SF1236; GE Silicones) ¹	33.31
Silicone fluid (DC200 350 cStk; Dow Corning) ²	7.89
Triclosan	0.30
Water	30.00
Xylitol	10.00
Glycerin	8.00
Xanthan Gum (Ketrol 1000) ⁴	0.30
Pemulen TR2 (BF Goodrich) ⁵	0.10
Methyl/Propyl parabens	0.10
TOTAL	100.00

Using an overhead mixer, add silicone fluid to silicone gum/fluid blend. Slowly add silicone resin (with triclosan pre-dispersed therein) to pre-weighed silicone fluid/gum blend till uniformly mixed and composition appears visually clear. Separately, disperse Pemulen in water under strong mixing. Dissolve xylitol and parabens in water/pemulen mix. Add into silicone premix under strong mixing. Predisperse Xanthan gum in glycerin and add to bulk under strong mixing.

Example 8:

INGREDIENT	% w/w
Silicone resin (TMS 803; Wacker Silicones) ³	10.00
Silicone gum/fluid blend (DC Q2 1403; Dow Corning) ¹	38.46

WO 02/34221

PCT/US00/29384

33

Triclosan	0.30
Water	32.64
Xylitol	10.00
Glycerin	8.00
Xanthan Gum (Ketrol 1000) ⁴	0.30
Pemulen TR2 (BF Goodrich) ⁵	0.10
Methyl/Propyl parabens	0.10
TOTAL	100.00

Using an overhead mixer, add silicone resin to gum/fluid blend (with triclosan pre-dispersed therein) till uniformly mixed and composition appears visually clear.

Separately, disperse Pemulen in water under strong mixing. Dissolve xylitol and parabens in water/pemulen mix. Add into silicone premix under strong mixing. Predisperse Xanthan gum in glycerin and add to bulk under strong mixing.

1 GE Silicones 260 Hudson River Road, Waterford, New York 12188, USA

2 Dow Corning 62, Rue General De Gaulle, 1310 La Hulpe, Brussels, Belgium

3 Wacker-Chemie GmbH, Silicones Division, Haans-Seidel-Platz 4, D-81737 Munchen, Germany

4 Kelco Dorset House, Regent Park, Kingston Road, Leatherhead, Surrey KT22 7PL, UK

5 BF Goodrich Rue de Verdunstraat, 742, B-1130, Brussels Belgium

WO 02/34221

PCT/US00/29384

34

CLAIMS

1. A non volatile composition that comprises:
 - i) from about 0.5% to about 60%, by weight, of a silicone resin;
 - ii) from about 0.1% to about 30%, by weight, of a silicone gum;
 - iii) from about 0.1% to about 95%, by weight, of a non volatile polysiloxane fluid which has a viscosity from about 1cStk to about 1000cStk; and
 - iv) from about 0.01% to about 50%, by weight, of an oral care active selected from teeth colour modifying substances, anti-tartar agents, anti-plaque agents, fluoride ion sources, anti-microbial agents, nutrients, antioxidants, H-2 antagonists, analgesics, anti-viral agents, mucosally absorbed pharmacological agents and mixtures thereof.
2. A composition according to Claim 1 wherein the silicone resin is selected from MQ resins with an M:Q ratio of from about 0.4 to about 0.8, preferably from about 0.6 to about 0.7.
3. A composition according to any of Claims 1 to 2 which comprises from about 2% to about 50%, preferably from about 10% to about 40%, even more preferably from about 15% to about 25%, by weight, of silicone resin.
4. A composition according to any of Claims 1 to 3 which comprises from about 1% to about 20%, preferably from about 1% to about 10%, more preferably from about 2% to about 7%, by weight, silicone gum.

WO 02/34221

PCT/US00/29384

35

5. A composition according to any of Claims 1 to 4 wherein the polysiloxane fluid has a viscosity from 2cStk about to about 500cStk, preferably from about 5cStk to about 400cStk.
6. A composition according to any of Claims 1 to 5 which comprises from about 5% to about 90%, more preferably from about 10% to about 85%, by weight, polysiloxane fluid.
7. A composition according to any of Claims 1 to 6 wherein the polysiloxane fluid is a polydimethylsiloxane fluid.
8. A composition according to any of Claims 1 to 7 wherein the weight ratio between the silicone resin and the silicone gum is in the range from about 0.1:1 to about 9:1, preferably from about 1:1 to about 7:1 and more preferably from about 1:1 to about 5:1.
9. A composition according to any of Claims 1 to 8 wherein the weight ratio between the polysiloxane fluid and the high molecular weight silicone gum is in the range from about 0.1:1 to about 20:1, preferably from about 1:1 to about 10:1, more preferably from about 2:1 to about 8:1 and even more preferably from about 2:1 to about 5:1.
10. A composition according to any of Claims 1 to 9 wherein the oral care active is selected from teeth colour modifying substances, anti-tartar agents, anti-plaque agents, fluoride ion sources, anti-microbial agents and mixtures thereof.
11. A composition according to any of Claims 1 to 10 wherein the oral care active is selected from peroxide, polyphosphates, xylitol, triclosan, stannous fluoride, soluble

WO 02/34221

PCT/US00/29384

36

zinc salts, potassium nitrate and mixtures thereof; preferably from peroxide, polyphosphates, xylitol, triclosan and mixtures thereof.

12. A composition according to any of Claims 1 to 11 which comprises from about 0.01% to about 20%, preferably from about 0.01% to about 10%, by weight, of an oral care active.
13. A composition according to any of Claims 1 to 11 wherein the composition is a water in silicone emulsion and wherein the emulsion comprises from about 5% to about 95%, preferably from about 25% to about 75%, more preferably from about 30% to about 60%, by weight, of the composition.
14. A composition according to Claim 13 wherein the internal aqueous phase comprises rheology modifiers selected from cellulose polymers, xanthum gum, carbomers, inorganic clay polymers, polycarboxylates, EO/PO block copolymers (poloxomers) thickening silicas and mixtures thereof.
15. A composition according to any of Claims 13 or 14 which comprises from about 0.001% to about 90%, preferably from about 5% to about 75%, even more preferably from about 10 % to about 60%, by weight, of water.
16. Use of a non volatile oral care silicone composition in the oral cavity to treat the hard and soft tissue surfaces wherein the composition comprises:
 - i) from about 0.5% to about 60%, by weight, of a silicone resin;
 - ii) from about 0.1% to about 30%, by weight of a silicone gum;
 - iii) from about 0.1% to about 95%, by weight, of a non volatile polysiloxane fluid which has a viscosity from about 1cStk to about 1000cStk.

WO 02/34221

PCT/US00/29384

37

17. Use of a composition according to Claim 16 wherein the composition also comprises an oral care active selected from teeth colour modifying substances, anti-tartar agents, anti-plaque agents, fluoride ion sources, anti-microbial agents, nutrients, antioxidants, H-2 antagonists, analgesics, anti-viral agents, mucosally absorbed pharmacological agents and mixtures thereof.

18. A non volatile composition that comprises:

- i) from about 0.1% to about 30%, by weight, of a methyl substituted polyorganosiloxane gum with a viscosity of greater than 500,000 cStk;
- ii) an M:Q polyorganosilxane resin wherein the M:Q ratio is in the range of 0.6-0.7;
- iii) a non volatile polydimethylsiloxane fluid which has a viscosity from about 5cStk to about 400cStk; and

wherein the weight ratio of polyorganosiloxane resin to polyorganosiloxane gum is in the range of from about 1:1 to about 7:1, wherein the weight ratio of polydimethylsiloxane fluid to polyorganosiloxane gum is in the range of from about 2:1 to about 8:1 and wherein the viscosity of the final composition is in the range of from about 1Pa.s to about 1000Pa.s.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/29384

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/16 A61K7/48 C08L83/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C08L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 10161 A (PROCTER & GAMBLE) 25 June 1992 (1992-06-25) cited in the application examples 1-6	18
X	----- DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 1999:518667 XP002170912 abstract & JP 11 222420 A (KANEBO) 17 August 1999 (1999-08-17)	18
E	----- WO 01 01942 A (PROCTER & GAMBLE) 11 January 2001 (2001-01-11) tables 2,6 ----- -/--	1-18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

25 July 2001

Date of mailing of the international search report

06/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fischer, J.P.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/29384

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 17059 A (PROCTER & GAMBLE) 15 May 1997 (1997-05-15) example 24 ---	18
E	WO 01 22923 A (DOW CORNING FRANCE) 5 April 2001 (2001-04-05) the whole document -----	18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/29384

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9210161 A	25-06-1992	AT 133065 T	15-02-1996
		AU 666471 B	15-02-1996
		AU 9108291 A	08-07-1992
		BR 9107150 A	16-11-1993
		CA 2097838 A,C	06-06-1992
		CN 1063037 A,B	29-07-1992
		CZ 9301057 A	16-03-1994
		DE 69116573 D	29-02-1996
		DE 69116573 T	19-09-1996
		DK 560879 T	03-06-1996
		EG 19657 A	30-08-1995
		EP 0560879 A	22-09-1993
		ES 2082447 T	16-03-1996
		FI 932563 A	04-06-1993
		GR 3018709 T	30-04-1996
		HK 1006151 A	12-02-1999
		HU 213538 B	28-07-1997
		HU 65092 A	28-04-1994
		IE 914215 A	17-06-1992
		JP 3046072 B	29-05-2000
		JP 6503580 T	21-04-1994
		KR 231309 B	15-11-1999
		MX 9102412 A	01-06-1992
		NO 931996 A	02-08-1993
		NZ 240854 A	27-01-1995
		PL 168061 B	30-12-1995
		PT 99697 A,B	30-10-1992
		SG 68554 A	16-11-1999
		SK 56493 A	06-04-1994
		TR 25548 A	01-05-1993
		US 5710113 A	20-01-1998
JP 11222420 A	17-08-1999	NONE	
WO 0101942 A	11-01-2001	AU 5602700 A	22-01-2001
		AU 5907300 A	22-01-2001
		AU 5907400 A	22-01-2001
		AU 5907500 A	22-01-2001
		WO 0101940 A	11-01-2001
		WO 0101941 A	11-01-2001
		WO 0101958 A	11-01-2001
		AU 5602600 A	22-01-2001
WO 9717059 A	15-05-1997	WO 0101939 A	11-01-2001
		AU 719603 B	11-05-2000
		AU 7476096 A	29-05-1997
		AU 721756 B	13-07-2000
		AU 7476196 A	29-05-1997
		AU 721752 B	13-07-2000
		AU 7522096 A	29-05-1997
		BR 9611420 A	23-02-1999
		BR 9611421 A	23-02-1999
		BR 9611431 A	23-02-1999
		CA 2236790 A	15-05-1997
		CA 2236942 A	15-05-1997
		CA 2236974 A	15-05-1997
		CZ 9801404 A	14-10-1998
		CZ 9801406 A	14-10-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/29384

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9717059 A		CZ 9801408 A	16-09-1998
		EP 0862411 A	09-09-1998
		EP 0862412 A	09-09-1998
		EP 0868169 A	07-10-1998
		HU 9900113 A	28-05-1999
		HU 9901986 A	29-11-1999
		JP 2000500135 T	11-01-2000
		JP 2000501074 T	02-02-2000
		JP 2000501075 T	02-02-2000
		NO 982033 A	07-07-1998
		NO 982034 A	07-07-1998
		NO 982035 A	07-07-1998
		NZ 321430 A	28-10-1999
		NZ 321800 A	28-10-1999
		PL 326676 A	12-10-1998
		PL 326679 A	12-10-1998
		PL 326705 A	26-10-1998
		SK 59298 A	04-11-1998
		SK 59398 A	04-11-1998
		SK 59498 A	04-11-1998
		TR 9800809 T	21-09-1998
		TR 9800810 T	21-09-1998
		TR 9800812 T	21-07-1998
		WO 9717057 A	15-05-1997
		WO 9717058 A	15-05-1997
		US 6074654 A	13-06-2000
		US 6139823 A	31-10-2000
		US 6071503 A	06-06-2000
		US 6019962 A	01-02-2000
WO 0122923 A	05-04-2001	NONE	